Acurx Pharmaceuticals Inc (ACXP) Stock Price, Quote & News

Company Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant st...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 533 1469

Website: www.acurxpharma.com

Address:

259 Liberty Avenue, Staten Island, United States

ShangVXO Aug. 19 at 1:17 PM

Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $IVF and $ACXP are very likable

0 · Reply

flcountryboy Aug. 18 at 4:29 PM

$ACXP Thoughts on expected dilution?

0 · Reply

JimmyOcarri Aug. 17 at 8:39 PM

$HSDT $YHC $ACXP $GP $CTNT ii

2 · Reply

STACKD0E Aug. 17 at 2:50 PM

$ACXP 🙃✨

0 · Reply

RTPRwire Aug. 17 at 2:42 PM

$ACXP is seeing a strong reaction on clinical trial results following a PR Newswire release. Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat RTPR pushed this release out to users at 8:01:00 AM ET

0 · Reply

ballyhooo Aug. 17 at 2:06 PM

$ACXP we got a name now how about an approval!

0 · Reply

focafoca99 Aug. 17 at 12:34 PM

$ACXP obtained FDA conditional acceptance and USPTO trademark allowance for its CIFBEZY brand name.

0 · Reply

Stock_Catcher Aug. 17 at 12:04 PM

$ACXP Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat

0 · Reply

_Jessikah_J_Liu_ Aug. 16 at 11:06 PM

Finalizing watchlist for next week. $ACXP & $VNRX both look bottomed following earnings. If they confirm I will look to scale some. I won't retire on these trades but a move back over VWAP would be fairly low-risk, respectable gains. My crush this week is obv $IPST . Continuation signals off a strong Friday push. Low float, low risk, low borrow. Known for triple-digit moves. Like $AIFA I think this one will give multiple trade opportunities. Good luck everyone!

1 · Reply

StocktwitsNews Aug. 14 at 5:52 PM

ACXP Q2 2026 Earnings Summary $ACXP https://stocktwits.com/news/earnings/ai summaries/acxp-q2-2026-earnings-summary/cZotYgmRJ0s

0 · Reply

Acurx announces FDA conditional approval of CIFBEZY as brand name for ibezapolst

Aug 17, 2026, 8:01 AM EDT - 2 days ago

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat

2026-08-17T09:42:22.000Z - 2 days ago

Acurx receives patents for DNA Polymerase IIIC inhibitors in Mexico and Japan

Aug 14, 2026, 8:00 AM EDT - 5 days ago

Acurx Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 14, 2026, 8:00 AM EDT - 5 days ago

Acurx Pharmaceuticals Quarterly report: Q2 2026

Aug 14, 2026, 8:00 AM EDT - 5 days ago

Acurx Pharmaceuticals Earnings release: Q2 2026

Aug 14, 2026, 7:01 AM EDT - 5 days ago

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update

Aug 12, 2026, 8:01 AM EDT - 7 days ago

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

2026-08-10T12:11:33.000Z - 9 days ago

Acurx partners with Leiden University Medical Center to develop its antibiotics

Aug 10, 2026, 8:01 AM EDT - 9 days ago

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

2026-08-03T12:05:14.000Z - 16 days ago

Acurx announces outcome of meeting with FDA on ibezapolstat’s clinical program

Aug 3, 2026, 8:00 AM EDT - 16 days ago

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

2026-07-14T12:10:22.000Z - 5 weeks ago

Acurx’s ibezapolstat shows microbe preservation efficacy

Jul 14, 2026, 8:00 AM EDT - 5 weeks ago

Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection

Jul 8, 2026, 8:00 AM EDT - 6 weeks ago

Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update

Jun 16, 2026, 8:00 AM EDT - 2 months ago

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

May 12, 2026, 8:00 AM EDT - 3 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Acurx Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Acurx Pharmaceuticals Earnings release: Q1 2026

May 12, 2026, 7:01 AM EDT - 3 months ago

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

2026-05-04T20:30:19.000Z - 3 months ago

Acurx files to sell 1.65M shares of common stock for holders

2026-05-04T20:29:36.000Z - 3 months ago

Acurx files to sell 1.3M shares of common stock for holders

May 4, 2026, 8:00 AM EDT - 3 months ago

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

May 4, 2026, 8:00 AM EDT - 3 months ago

Acurx Pharmaceuticals Registration statement: Registration filing

May 4, 2026, 8:00 AM EDT - 3 months ago

Acurx Pharmaceuticals Registration statement: Registration filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update

Apr 16, 2026, 4:01 PM EDT - 4 months ago

Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

2026-04-16T14:19:45.000Z - 4 months ago

Acurx announces $7.1M registered direct offering priced at-the-market

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

2026-04-07T13:33:21.000Z - 4 months ago

New to The Street announce re-signing of Acurx Pharmaceuticals

2026-03-30T11:05:37.000Z - 5 months ago

Acurx: KIPO grantes new patent covering DNA Polymerase IIIC inhibitors

Mar 30, 2026, 7:01 AM EDT - 5 months ago

Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

2026-03-13T16:50:20.000Z - 5 months ago

Acurx price target lowered to $10 from $20 at Alliance Global

Mar 13, 2026, 8:00 AM EDT - 5 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 13, 2026, 8:00 AM EDT - 5 months ago

Acurx Pharmaceuticals Earnings release: Q4 2025

Mar 13, 2026, 8:00 AM EDT - 5 months ago

Acurx Pharmaceuticals Annual report: Q4 2025

Mar 13, 2026, 7:01 AM EDT - 5 months ago

Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

2026-03-13T00:49:02.000Z - 5 months ago

Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate

2026-03-09T12:05:07.000Z - 5 months ago

Acurx announces new ibezapolstat clinical trial program

Mar 9, 2026, 8:01 AM EDT - 5 months ago

Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection

Feb 16, 2026, 8:01 AM EST - 6 months ago

Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

2026-02-02T21:50:10.000Z - 7 months ago

Acurx files to sell 750,000 shares of common stock for holders

2026-02-02T13:06:26.000Z - 7 months ago

Acurx awarded patent covering DNA Polymerase IIIC inhibitors by USPTO

Feb 2, 2026, 8:00 AM EST - 7 months ago

USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

Feb 2, 2026, 7:00 AM EST - 7 months ago

Acurx Pharmaceuticals Registration statement: Registration Filing

Dec 30, 2025, 7:00 AM EST - 8 months ago

Acurx Pharmaceuticals Registration statement: Registration Filing

Nov 18, 2025, 8:00 AM EST - 9 months ago

Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

Nov 12, 2025, 8:00 AM EST - 10 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Acurx Pharmaceuticals Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Acurx Pharmaceuticals Quarterly report: Q3 2025

Nov 12, 2025, 7:01 AM EST - 10 months ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

Nov 10, 2025, 8:00 AM EST - 10 months ago

Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Acurx Pharmaceuticals Registration statement: Registration Filing

Oct 20, 2025, 7:00 AM EDT - 10 months ago

Acurx Pharmaceuticals Slides: Conference presentation

Oct 9, 2025, 7:30 AM EDT - 11 months ago

Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Sep 30, 2025, 7:30 AM EDT - 11 months ago

Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection

Sep 3, 2025, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules

Aug 28, 2025, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Slides: Study update presentation

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Quarterly report: Q2 2025

Aug 12, 2025, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing

Jul 31, 2025, 9:25 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

Jul 24, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing

Jul 24, 2025, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update

Jul 15, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Registration statement: Registration Filing

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Registration statement: Registration Filing

Jun 17, 2025, 9:47 PM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

Jun 17, 2025, 7:01 AM EDT - 1 year ago

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

Jun 9, 2025, 7:30 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

May 29, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing

May 29, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing

May 21, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Registration statement: Registration Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing

May 13, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

Apr 17, 2025, 7:30 AM EDT - 1 year ago

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Registration statement: Registration Filing

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings release: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Annual report: Q4 2024

Mar 18, 2025, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 10, 2025, 4:30 PM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

Mar 7, 2025, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Mar 3, 2025, 8:00 AM EST - 1 year ago

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Feb 28, 2025, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

Feb 24, 2025, 8:00 AM EST - 1 year ago

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Feb 19, 2025, 8:00 AM EST - 1 year ago

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

Jan 31, 2025, 7:00 AM EST - 1 year ago

Acurx Pharmaceuticals Registration statement: Registration Filing

Jan 7, 2025, 5:00 PM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 5:35 PM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 8:30 AM EST - 1 year ago

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Dec 11, 2024, 11:00 AM EST - 1 year ago

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Dec 9, 2024, 8:00 AM EST - 1 year ago

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Nov 20, 2024, 10:53 AM EST - 1 year ago

Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook

ShangVXO Aug. 19 at 1:17 PM

0 · Reply

flcountryboy Aug. 18 at 4:29 PM

$ACXP Thoughts on expected dilution?

0 · Reply

JimmyOcarri Aug. 17 at 8:39 PM

$HSDT $YHC $ACXP $GP $CTNT ii

2 · Reply

STACKD0E Aug. 17 at 2:50 PM

$ACXP 🙃✨

0 · Reply

RTPRwire Aug. 17 at 2:42 PM

0 · Reply

ballyhooo Aug. 17 at 2:06 PM

$ACXP we got a name now how about an approval!

0 · Reply

focafoca99 Aug. 17 at 12:34 PM

$ACXP obtained FDA conditional acceptance and USPTO trademark allowance for its CIFBEZY brand name.

0 · Reply

Stock_Catcher Aug. 17 at 12:04 PM

$ACXP Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat

0 · Reply

_Jessikah_J_Liu_ Aug. 16 at 11:06 PM

1 · Reply

StocktwitsNews Aug. 14 at 5:52 PM

ACXP Q2 2026 Earnings Summary $ACXP https://stocktwits.com/news/earnings/ai summaries/acxp-q2-2026-earnings-summary/cZotYgmRJ0s

0 · Reply

Cpictures Aug. 14 at 2:47 PM

$ACXP Friendly reminder that this is not a real company. There are no research labs or offices - it is a couple of old guys with a patent "working" from home. There will be no phase 3 trial. Their "product" is stock offerings which goes to fund the salaries of said old men. They will keep the game going until it is delisted.

0 · Reply

Agge11 Aug. 14 at 1:29 PM

$BAOS $ACXP $ONFO $CAST $DARE

0 · Reply

Agge11 Aug. 14 at 1:29 PM

$ACXP 10 $ today 🚀🚀🚀🚀💪

0 · Reply

StocktwitsEarnings Aug. 14 at 1:04 PM

$ACXP Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.53 up 71.96% YoY

0 · Reply

focafoca99 Aug. 14 at 11:13 AM

$ACXP is reporting Q2 2026 results, closing a $2.5M direct offering and ending the quarter with $10.7M cash.

0 · Reply

Toptradersam Aug. 14 at 9:45 AM

$BAOS $ACXP $ONFO $CAST $DARE This one is back on my radar! 📈 I’m watching for a potential high-volatility bounce and looking for the right entry instead of chasing the spike. https://www.youtube.com/watch?v=EpAfFgljOJY

0 · Reply

dpdlwnl12 Aug. 12 at 3:40 PM

$ACXP is expected to surge this afternoon. 🚀🚀🚀 Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program. According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections.

0 · Reply

dpdlwnl12 Aug. 12 at 3:35 PM

$VBIO $ACXP is expected to surge this afternoon. 🚀🚀🚀 Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program. According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections.

1 · Reply

dpdlwnl12 Aug. 12 at 3:32 PM

$WCT $ACXP is expected to surge this afternoon. 🚀🚀🚀 Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program. According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections..

0 · Reply

dpdlwnl12 Aug. 12 at 3:31 PM

$SBEV $ACXP is expected to surge this afternoon. 🚀🚀🚀 Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program. According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections.

0 · Reply

dpdlwnl12 Aug. 12 at 3:31 PM

$BIVI $ACXP is expected to surge this afternoon. 🚀🚀🚀 Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program. According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections...

0 · Reply

dpdlwnl12 Aug. 12 at 3:30 PM

$OFAL $ACXP is expected to surge this afternoon. 🚀🚀🚀 Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program. According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections..

0 · Reply

Market Cap	7.09M
Revenue (ttm)	0.00
Net Income (ttm)	-7.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	267,300
Avg Vol	126,518
Day's Range	N/A - N/A
Shares Out	4.30M
Stochastic %K	26%
Beta	-2.03
Analysts	Strong Sell
Price Target	$17.00